Gil M. Labrucherie
2017
In 2017, Gil M. Labrucherie earned a total compensation of $7.8M as Senior Vice President and Chief Financial Officer at Nektar Therapeutics, a 184% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $531,475 |
|---|---|
| Option Awards | $3,672,084 |
| Salary | $607,400 |
| Stock Awards | $2,958,794 |
| Other | $10,338 |
| Total | $7,780,091 |
Labrucherie received $3.7M in option awards, accounting for 47% of the total pay in 2017.
Labrucherie also received $531.5K in non-equity incentive plan, $607.4K in salary, $3M in stock awards and $10.3K in other compensation.
Rankings
In 2017, Gil M. Labrucherie's compensation ranked 1,001st out of 14,666 executives tracked by ExecPay. In other words, Labrucherie earned more than 93.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,001 out of 14,666 | 93rd |
Division Manufacturing | 338 out of 5,772 | 94th |
Major group Chemicals And Allied Products | 87 out of 2,075 | 96th |
Industry group Drugs | 58 out of 1,731 | 97th |
Industry Pharmaceutical Preparations | 48 out of 1,333 | 96th |
Source: SEC filing on April 30, 2018.
Labrucherie's colleagues
We found four more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2017.
2017
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2017
John Nicholson
Nektar Therapeutics
Chief Operating Officer
2017
Stephen Doberstein
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2017
Maninder Hora
Nektar Therapeutics